Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
A gut bacterium, Clostridium steroidoreducens, can chemically modify steroid hormones, including those used to treat IBD.
L. mucosae and L. ruminis can produce serotonin in the gut, where it promotes nerve growth and regulates intestinal motility.
Researchers have found that certain gut bacteria and their metabolites differ between IBS subtypes.
Changes in gut bacteria, especially Akkermansia, could predict treatment success in people with lung cancer.
Ethical, long-term partnerships can uncover valuable scientific insights while respecting Indigenous knowledge.
Controlling cadaverine levels and the gut bacteria that produce it could help regulate immune cell metabolism and inflammation.
Environments and social factors shape human microbiotas.
The abundance of Bifidobacterium may explain M116’s excellent cholesterol profile and low inflammation levels.
The authors propose a coordinated framework involving policymakers, scientists, educators, and communities to embed microbiota science into One Health strategies.
Targeting gut bacteria or butyrate could be a promising therapy for glioma.
